Posters

Sep 2024

ESMO Congress 2024

Primary Results from TACTI-003: A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble LAG-3) Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS >1

Jul 2024

ESMO Virtual Plenary

Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma: Primary Results from Cohort B (CPS <1) of the TACTI-003 Study

Jun 2024

ASCO

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Jun 2024

ASCO

IKF614/INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)

ESMO Breast

Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003

Publications

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

S.-E. Al-Batran, D.W. Mueller, M.-R. Rafiyan, D. Kiselicki, A. Atmaca, T. Habibzada, C. Mueller, C. Brignone, F. Triebel, M. Loose, M. Schaaf, D. Sookthai, R. Eickhoff, E. Jaeger, T.O. Goetze ESMO Open Volume 8, Issue 5, October 2023, 101623

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

Jin-Ling Huo, Ya-Tao Wang, Wen-Jia Fu, Nan Lu, Zhang-Suo Liu Front. Immunol., 26 July 2022 Sec. Cancer Immunity and Immunotherapy https://doi.org/10.3389/fimmu.2022.956090

Clinical landscape of LAG-3-targeted therapy

L. Chocarro, E. Blanco, H. Arasanz, L. Fernández-Rubio, A. Bocanegra, M. Echaide, M. Garnica, P. Ramos, G. Fernández-Hinojal, R. Vera, G. Kochan & D. Escors. IOTECH: Immuno-Oncology and Technology Review March 2022

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Schöffski P, Tan DSW, Martín M, et al. Journal for ImmunoTherapy of Cancer January 2022;10:e003776. doi:10.1136/ jitc-2021-003776

Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes

Erdal Sag, Selcan Demir, Maithri Aspari, Morten Aagaard Nielsen, Cæcilie Skejø, Malene Hvid, Egemen Turhan, Yelda Bilginer, Stinne Greisen, Seza Ozen and Bent Deleuran. May 2021. Pediatric Research